Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

13

Revenue 2017

Harvoni

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Harvoni was produced by Bristol-Myers Squibb.

Gilead must pay just $200m for hep C patents, says jury

Gilead must pay just $200m for hep C patents, says jury Merck &Co awarded a 4% royalty rate on sales of Sovaldi and Harvoni. ... Merck had been pushing for a 10% royalty rate on the $20.7bn Gilead had made from sales of two sofosbuvir-based drugs - Sovaldi and Harvoni - between 2013 and 2015, after

Merck & Co wins hepatitis C patent dispute with Gilead

Merck & Co wins hepatitis C patent dispute with Gilead The jury in the lawsuit upheld Merck's claim that Gilead's sofosbuvir - which features in its massive-selling Sovaldi and Harvoni HCV drugs - infringes two patents it holds alongside Ionis ... Gilead is also in the throes of a lawsuit with AbbVie, which

Harvoni cleared for broader use in hepatitis C

Harvoni cleared for broader use in hepatitis C and Merck &Co's recently-approved Zepatier (elbasvir/grazoprevir), which has undercut Harvoni on price. ... The company is also hoping to launch a follow-up to Harvoni, which covers a broader range of HCV genotypes and should extend the franchise.

The big picture

The big picture They actually went out and did two separate economic evaluations and determined that Sovaldi and its close cousin, Harvoni are cost-effective.

Merck & Co's oral hepatitis C therapy approved in US

Merck & Co's oral hepatitis C therapy approved in US The undisputed market leader at the moment is Gilead Sciences with its Harvoni (sofosbuvir/ledipasvir) combination and single-agent product Sovaldi (sofosbuvir), with AbbVie also pressing for market share with its ... For example, at undiscounted prices

[ Previous 5 results ] 3 4 5 6 7 8 9 10 11 12 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

OPEN Health expands offering with the launch of a new Learning & Development specialist team
Enhanced expertise to deliver impactful internal training programmes for healthcare clients...
Figure 1 Clarivate
The changing nature of approvals – what does the future hold?
The 2019 CMR International Pharmaceutical R&D Factbook...
Spotlight interview: 15 minutes on healthcare communications in gene therapy
Gavin Jones, Director of Rare Disease, OPEN Health takes 15 minutes to answer some key questions on healthcare communications in gene therapy...

Infographics